Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 4/20 | 0.84 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 2/20 | 0.53 |
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | NOS2 | P35228 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629225 | 0.92 | SCN2A (0.80) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4628674 | 0.92 | SCN2A (0.83) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4628980 | 0.92 | SCN2A (1.00) | SCN2APARP10ALDH1A1MAPTNOS3 | |
| SCHEMBL4627476 | 0.89 | SCN2A (0.69) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4628715 | 0.86 | SCN2A (0.72) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4628743 | 0.86 | SCN2A (0.67) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4628948 | 0.85 | SCN2A (0.67) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4627497 | 0.84 | SCN2A (0.66) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4628807 | 0.84 | SCN2A (0.66) | SCN2ANPC1RAB9ASMN1; SMN2PARP10 | |
| SCHEMBL4628996 | 0.83 | SCN2A (0.65) | SCN2ANPC1RAB9APARP10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN2A 1613/4885NPC1 140/4885RAB9A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.